In clinics, the effects of PD-L1 inhibitors, such as pembrolizumab, on thyroid cancer have been actively investigated in recent years, but the number of patients who responded to the treatment was small [79], suggesting that immunotherapy may have limited effects on the cancer [80]. The gene discussed is CD274; the disease is thyroid gland carcinoma.